University of Texas Southwestern Medical Center: Department of Internal Medicine, Division of Endocrinology
Welcome,         Profile    Billing    Logout  
 6 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gitelman, Stephen
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Recruiting
2
78
US
Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer
Diabetes Mellitus, Type 1
06/26
06/27
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Recruiting
2
74
US, RoW
Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type 1 Diabetes Mellitus
10/27
10/29
TN28, NCT04291703: STOP-T1D Low-Dose (ATG)

Active, not recruiting
2
101
US, RoW
Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
12/28
12/29
DESIGNATE, NCT05574335: Siplizumab in T1DM

Active, not recruiting
1/2
120
US
Siplizumab, TCD 601
National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
12/26
12/27
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Completed
1
47
US
NNC0361-0041, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S
Type I Diabetes
08/23
04/24
T1DES, NCT02734277: Type 1 Diabetes Extension Study

Recruiting
N/A
111
US
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN)
Type 1 Diabetes Mellitus, T1DM, T1D
03/25
03/25
NCT00097292: TrialNet Pathway to Prevention of T1D

Recruiting
N/A
75000
Europe, Canada, US, RoW
University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Diabetes Association, National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR)
Diabetes Mellitus, Type 1
07/25
07/25
Raskin, Philip
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Completed
4
141
US
Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1
03/24
06/24
DESIGNATE, NCT05574335: Siplizumab in T1DM

Active, not recruiting
1/2
120
US
Siplizumab, TCD 601
National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
12/26
12/27
2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes

Completed
N/A
319
Canada, US
t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Tandem Diabetes Care, Inc., Jaeb Center for Health Research
Type 2 Diabetes Treated With Insulin
09/24
09/24
Sao, Serey
DESIGNATE, NCT05574335: Siplizumab in T1DM

Active, not recruiting
1/2
120
US
Siplizumab, TCD 601
National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
12/26
12/27
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Completed
1
47
US
NNC0361-0041, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S
Type I Diabetes
08/23
04/24
Hemann, Holly
DESIGNATE, NCT05574335: Siplizumab in T1DM

Active, not recruiting
1/2
120
US
Siplizumab, TCD 601
National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
12/26
12/27

Download Options